Aug 15
Opportunity
Clinical trial participants would like more data returned to them during and after participation in clinical trials; however, the frequency, timing and type of data returned to participants today is varied and inconsistent. This opportunity provides participants with the option of receiving their study data / results in the format and at the time they choose.
Considerations to Help Action the Opportunity
- Address individual participant data return issues early in the clinical development planning process
- Ensure security of participant privacy, confidentiality, flexibility and safety while maintaining scientific integrity and product approval timelines
- Prioritize and personalize optionality in delivery and content as best as possible
- Provide support to sites, HCPs, participants and their care partners regarding management of individual data to optimize access, inclusiveness and health equity
- Understand how digital technologies and existing cross collaborations can be optimized to facilitate interoperability of systems which collect and manage patient / participant clinical care and clinical research data
Value and Potential Benefits
- Demonstrates respect and gratitude for the participant’s contributions to scientific advancements in research and development
- Enhances patient partnerships and autonomy
- Informs patients and increases awareness about clinical trials and enhances public trust, fairness and transparency
- Improves clinical trial engagement and the participant experience, potentially facilitating recruitment and retention
- Utilizes a proactive approach to achieve operational efficiencies by being prepared for unplanned requests for individual data
- Empowers participants to be more active decision makers when it comes to the use of the data they contribute to improve health outcomes
- Reduces the burden on participants and health systems by reducing repeated testing / exams, where possible
Related Blog Posts
A New Era in Advancing Care for Pregnant and Breastfeeding Patients
One major challenge facing the clinical research ecosystem is not whether, but how to study drug safety and efficacy in pregnant and breastfeeding populations. A growing number of organizations—including the ICH E21 Expert Working Group (EWG) and TransCelerate’s Interpretation of Pharmacovigilance Guidances & Regulations (IGR PV) initiative—are diligently seeking ethical and responsible solutions to protect these…
Improving Medicine Use During Pregnancy & Breastfeeding: Forging a Path Forward
The scientific community intended to protect pregnant and breastfeeding populations when it strictly limited their involvement in clinical trials after the thalidomide crisis of the 1950s-1960s. Yet over the past few decades, people have increasingly recognized the real-life challenges posed by the lack of research into the safety of medications used during pregnancy and breastfeeding.…
Transforming Pharmacovigilance: Solutions to Solve Regulatory Challenges
Patient safety depends partly on sponsor organizations’ compliance with pharmacovigilance (PV) regulatory requirements—even when global variations exist. Helping sponsors interpret and operationalize challenging PV regulations and guidances is the goal of TransCelerate’s Interpretation of Pharmacovigilance Guidances & Regulations (IGR PV) initiative. In this third installment of our IGR PV blog series, we will examine the solutions…